Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

Subjects:

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

Subjects:

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

Subjects:

Characteristics of the included studies. by Si He (3236646)

Subjects:

Trial sequential analysis of primary outcomes after negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Trial sequential analysis of secondary outcomes after negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects:

Pooled effect of the therapeutic effects of negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Forest plots of secondary outcomes after negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Extracted data and used for analysis. by Si He (3236646)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Excluded studies with reasons for exclusion. by Si He (3236646)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Flow diagram of the studies included in the meta-analysis. by Si He (3236646)

Subjects:

Stairway plot representing inferred changes in effective population size (<i>N</i>_e) over time for the Greater Liuwa Ecosystem brindled wildebeest population. by Stephanie J. Szarmach (21175477)

Subjects:

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”